BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
See today's BioWorld
Home
» Minerva's top-line results for phase IIb seltorexant trial can't budge the stock
To read the full story,
subscribe
or
sign in
.
Minerva's top-line results for phase IIb seltorexant trial can't budge the stock
May 14, 2019
By
Lee Landenberger
Results from Minerva Neurosciences Inc.'s phase IIb study of seltorexant (MIN-202) announced on Monday bode well for further studies of the drug but couldn't bump the company stock out of the doldrums.
BioWorld
